Cite
RWD149 Real-World Comparison of Cardiovascular Benefits between Sodium-Glucose Cotransporter 2 (SGLT-2I) and Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Inhibitors in Patients with Type 2 Diabetes (T2D).
MLA
Huang, D., et al. “RWD149 Real-World Comparison of Cardiovascular Benefits between Sodium-Glucose Cotransporter 2 (SGLT-2I) and Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Inhibitors in Patients with Type 2 Diabetes (T2D).” Value in Health, vol. 26, no. 6, June 2023, p. S389. EBSCOhost, https://doi.org/10.1016/j.jval.2023.03.2178.
APA
Huang, D., Greenwood, B., Salsabili, M., Tesell, M., & Alcusky, M. (2023). RWD149 Real-World Comparison of Cardiovascular Benefits between Sodium-Glucose Cotransporter 2 (SGLT-2I) and Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Inhibitors in Patients with Type 2 Diabetes (T2D). Value in Health, 26(6), S389. https://doi.org/10.1016/j.jval.2023.03.2178
Chicago
Huang, D., B. Greenwood, M. Salsabili, M. Tesell, and M. Alcusky. 2023. “RWD149 Real-World Comparison of Cardiovascular Benefits between Sodium-Glucose Cotransporter 2 (SGLT-2I) and Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Inhibitors in Patients with Type 2 Diabetes (T2D).” Value in Health 26 (6): S389. doi:10.1016/j.jval.2023.03.2178.